Startups

Synchron

New York, New York · Melbourne, Australia · New York, United States

Private endovascular brain-computer interface company developing the investigational Stentrode. Founded by Thomas Oxley and Nicholas Opie; operations also in Melbourne and San Diego.

Founded 2012

Team

Alex MorganBoard Member

Andy RasdalChief of Staff and board director, appointed August2025

Ari NowacekBoard Member

Kurt HaggstromChief Commercial Officer

Mark BristerVP Research and Development, appointed August2025

Martin DieckChairman of the Board

Nicholas OpieCo-founder / founding director

Rahul SharmaMedical Director and Co-Founder

Thomas OxleyCo-founder and CEO

Investments

$200M2025-11-06	Double Point Ventures, ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, Neuro Technology Investors, METIS Innovative, National Reconstruction Fund Corporation, T.Rx Capital, Qatar Investment Authority, K5 Global, Protocol Labs, IQT
$75M2022-12-15	ARCH Venture Partners, Bezos Expeditions, Khosla Ventures, Gates Frontier, Reliance Digital Health, Greenoaks, Alumni Ventures, Moore Strategic Ventures, Project X, Neuro Technology Investors, METIS Innovative, Forepont Capital Partners, ID8 Investments, Shanda Group, University of Melbourne
$40M2021-06-03	Khosla Ventures, Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital, re.Mind Capital, Arani Bose, Thomas Reardon, Neuro Technology Investors, METIS Innovative, University of Melbourne
$10M2017-04-04	Neuro Technology Investors
$—Unknown date	Kaleida Capital

team@apexlogos.ai14 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: Synchron. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # Synchron Research date: **2026-10-06**. Review material only; no adex data was modified. All linked sources and HTML image references were accessed on this date. ## Identity and operating status **Synchron Inc.**, private endovascular neurotechnology company. Founded **2012** by Thomas (Tom) Oxley and Nicholas (Nick) Opie; headquarters New York with operations in Melbourne and San Diego. [Official about](https://synchron.com/about); [Co-founder institutional biography](https://pursuit.unimelb.edu.au/individuals/associate-professor-nicholas-opie) Develops Stentrode endovascular brain sensing/communication interface. Official disclaimer says investigational and not commercially approved for use in any geography; active clinical development is distinct from commercial device approval. ## Audit of pasted BCI.INTEL entry | Pasted claim | Assessment | |---|---| | New York HQ; Tom Oxley CEO | Supported by company releases and institutional profile. | | $345M total | Dated 2025 financing release confirms reported total; not independently audited equity-only aggregate. | | Ticker $200M Series D | Confirmed 2025-11-06. | | Stentrode active | Genuine investigational endovascular system. | ## Company profile image Direct company logo: [PNG](https://synchron.com/assets/synchron-logo.png) from official about-page image with alt Synchron. Team PFPs in table; no images downloaded. ## Founders and public team | Person | Role / relationship | Profile and role evidence | Direct profile image URL | |---|---|---|---| | Tom Oxley | Co-founder and CEO | [Role/profile source](https://profiles.mountsinai.org/thomas-j-oxley) | [PFP](https://www.mountsinai.org/files/images/fad-images/0000076810056181148661.jpg) | | Nick Opie | Co-founder / founding director | [Role/profile source](https://pursuit.unimelb.edu.au/individuals/associate-professor-nicholas-opie) | [PFP](https://pursuit.unimelb.edu.au/__data/assets/image/0022/85513/varieties/160w.jpg) | | Andy Rasdal | Chief of Staff and board director, appointed August2025 | [Role/profile source](https://www.businesswire.com/news/home/20250819583131/en/Synchron-Expands-Executive-Team-with-Appointment-of-Andy-Rasdal-as-Chief-of-Staff-and-Mark-Brister-as-VP-RD) | Unavailable; examined cited official/institutional profile; no named portrait URL verified | | Mark Brister | VP Research and Development, appointed August2025 | [Role/profile source](https://www.businesswire.com/news/home/20250819583131/en/Synchron-Expands-Executive-Team-with-Appointment-of-Andy-Rasdal-as-Chief-of-Staff-and-Mark-Brister-as-VP-RD) | Unavailable; examined cited official/institutional profile; no named portrait URL verified | Current public site does not provide a full named leadership gallery. Existing adex Rahul Sharma CTO relationship was not reconfirmed from examined current primary pages; do not interpret old titles or employee lists as current. Institutional portraits above are named biography assets. ## Investments and financing | Announced date | Round | USD amount | Lead | Other named investors | Evidence | |---|---|---:|---|---|---| | 2017-04-04 | Series A completion | $10M | NeuroTechnology Investors | Full participating set not established | [Issuer PRNewswire](https://www.prnewswire.com/news-releases/synchron-inc-secures-10-million-in-series-a-financing-round-300433942.html) | | 2021-06-03 | Series B | $40M | Khosla Ventures | Forepont; ID8; Shanda; General Advance; Subversive; re.Mind; Arani Bose; Thomas Reardon; NTI; METIS; University of Melbourne | [Company-issued release republication](https://www.neurofounders.co/press-releases/synchron-secures-40m-in-series-b-led-by-khosla-ventures-to-launch-u-s-clinical-trials) | | 2022-12-15 | Series C | $75M | ARCH Venture Partners | New: Gates Frontier; Bezos Expeditions; Reliance Digital Health; Greenoaks; Alumni Ventures; Moore Strategic Ventures; Project X. Existing: Khosla; NTI; METIS; Forepont; ID8; Shanda; University of Melbourne | [Release hosted by investor Reliance](https://www.ril.com/sites/default/files/2023-01/MR15122022.pdf) | | 2025-11-06 | Series D | $200M | Double Point Ventures | Existing ARCH; Khosla; Bezos; NTI; METIS. New NRF Australia; T.Rx Capital; QIA; K5 Global; Protocol Labs; IQT | [Issuer Business Wire](https://www.businesswire.com/news/home/20251106150841/en/Synchron-Raises-%24200-Million-Series-D-to-Advance-Brain-Computer-Interface-Technology) | Headline rounds sum **$325M** versus company-reported **$345M total**, so the table is not a lifetime reconciliation. The 2021 release reports $59M cumulative **including government support**. Separate support includes a $10M NIH award announced in2021 on [official news index](https://synchron.com/news); award period/recipient must be verified before adding a grant record. DARPA historical support is not an equity investor merely because aggregators list it. No acquisition/debt close independently established here. ## Existing adex match and review decision Existing `Synchron`; enrich instead of duplicate. Keep funding as dated reported total and individual sourced rounds; resolve current CTO and grant accounting before import. Read-only `Org` lookup found the following records. The snapshot below records existing claims, **not verification of those claims**.
team@apexlogos.ai22 days ago
COMPETITION